Investigation of the effect of increasing days of abitant capsul use in control of chemotherapy induced nausea and vomiting with AC regimen in women with breast cancer

Effect of increase in duration of Aprepitant consumption from 3 to 6 days on the prevention of nausea and vomiting in women receiving combination of Anthracycline/Cyclophosphamide chemotherapy: A randomized, crossover, clinical trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015040121574N1

Enrollment

Registered

2015-06-20

Start date

2015-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Chemotherapy induced nausia and vomitting. Condition 2: Breast cancer. Antineoplastic and immunosuppressive drugs, Poisoning by primarily systemic and haematological agents, not elsewhere classifiedAntineoplastic and immunosuppressive drugs Malignant neoplasm of breast

Interventions

Intervention 1: 6 days consumption of Abitant capsul. Intervention 2: 3 days consumption of Abitant capsul.

Treatment - Drugs

6 days consumption of Abitant capsul

3 days consumption of Abitant capsul

Eligibility

Sex/Gender

Female

Age

24 Years to 50 Years

Inclusion criteria

Inclusion criteria: General inclusion criteria: Less than 50 years of age, diagnosed with breast cancer and scheduled to receive 4 courses Anthracycline/Cyclophosphamide (AC) regimens. General exclusion criteria: previous history of gastritis, diabetes and brain tumor.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Complete response. Timepoint: 6 days after begining of intervention. Method of measurement: Questionnaire based on ECOG criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Simin Hemmati

Esfahan university of medical science

hemati@med.mui.ac.ir+98 31 3793 2335

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026